对复发/难治性B细胞急性淋巴细胞白血病成人患者的抗原靶向抗体和细胞疗法进行测序。
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
作者信息
Aldoss Ibrahim, Shah Bijal D, Park Jae H, Muffly Lori, Logan Aaron C, Brown Patrick, Stock Wendy, Jabbour Elias J
机构信息
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.
出版信息
Am J Hematol. 2023 Apr;98(4):666-680. doi: 10.1002/ajh.26853. Epub 2023 Feb 6.
The recent approvals of four CD19-or CD22-targeted therapies for B-cell acute lymphoblastic leukemia (B-ALL) have transformed the treatment of relapsed/refractory (r/r) disease. Adults with r/r B-ALL are usually eligible for all options, but there are no studies directly comparing these agents, and the treating physician must decide which to select. Each therapy has notable activity as a single agent but has limitations in particular settings, and the optimal choice varies. These therapies can be complementary and used either sequentially or concomitantly. Here, we review the current landscape of antigen-targeted therapies for r/r B-ALL and discuss considerations for their use.
最近，四种针对CD19或CD22的疗法被批准用于治疗B细胞急性淋巴细胞白血病（B-ALL），这彻底改变了复发/难治性（r/r）疾病的治疗方式。患有r/r B-ALL的成人通常有资格选择所有治疗方案，但尚无直接比较这些药物的研究，治疗医生必须决定选择哪种药物。每种疗法作为单一药物都有显著疗效，但在特定情况下存在局限性，最佳选择也因人而异。这些疗法可以相互补充，可序贯使用或联合使用。在此，我们综述了目前用于r/r B-ALL的抗原靶向疗法的现状，并讨论了其使用时的注意事项。
Zotero 插件